Frankenfield Christopher James's Form 4 filing
Xilio Therapeutics, Inc. (XLO) · filed Jan 3, 2025
- Accession no.
- 0001415889-25-000407
- Filed
- Jan 3, 2025
- Trade date
- Jan 1-2, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market sales total $6.81K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Frankenfield Christopher JamesCIK 0001988344 | Officer (Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2025 | Common Stock | MOption exerciseAcquired | +19,375 | – | – | 19,375 | Direct | |
| Jan 2, 2025 | Common stock | SSaleDisposed | −6,954 | $0.98 | −$6,814.92 | 12,421 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 1, 2025 | Common Stock | MOption exerciseDisposed | −19,375 | $0.00 | $0 | 58,125 | Direct | |
| Jan 1, 2025 | Common Stock | AGrant or awardAcquired | +251,000 | $0.00 | $0 | 251,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.